Unrelated drugs with one thing in common: they oxidise. In a G6PD-deficient person that is enough to break red cells at an ordinary dose, and in most cases there is something else to prescribe.
What this drug connects to
Solid lines are connections this site curates. Dashed lines mean the two ends share a research paper — worth knowing, and not a claim that one explains the other.
All are oxidising agents that can precipitate acute haemolysis in a G6PD-deficient person at ordinary doses. In most cases an alternative exists, which is why knowing the phenotype before prescribing is the whole point — there is nothing to do about the deficiency itself. Toluidine blue, a dye closely related to methylene blue and used to stain tissue during surgery, is on the same list for the same reason, and is the kind of exposure nobody thinks of as a prescription.
CPIC Guideline for G6PD Genotype and Medication Use (Clin Pharmacol Ther 2023, PMID 36049896).
Whose work this rests on
Every guideline above was written by people. Named here because they are contributors to this page in the same sense anybody else on this site is.
Clinical pharmacology and therapeutics · 2023 · PMID 36049896
Variants MyGeneLog reports for these genes
These are the positions in your own file that carry the genes above. Not every gene in a guideline is one we report — where that is the case the gene appears above without a variant here, and the note says so.
This page is educational and contains no dosing information. Where a clinical guideline covers one of these gene-drug pairs it is written for prescribers and works through validated algorithms alongside clinical monitoring. Nothing here is a reason to start, stop, or change a medication — that conversation belongs with the clinician or pharmacist managing your treatment.